March 9 (Reuters) - Vertex Pharmaceuticals said on Monday that its experimental kidney disease drug met the main goal of a ...

First new drug in 30 years to slow kidney disease in type 1 diabetes ...

News, features, and commentary about cancer-related issues ...

Vertex Pharmaceuticals Inc. shares rose as much as 11% in late trading Monday after the biotech company said its drug to treat a kidney disorder met its goal in a late-stage trial, providing a boost ...

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney disease known as IgA nephropathy.

By Kamal Choudhury March 9 (Reuters) - Vertex Pharmaceuticals said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a late‑stage trial, putting the company on track ...

The Syrian Ministry of Health received On Monday, 10 trucks loaded with medicines and medical supplies designated for ...

Shares of Vertex Pharmaceuticals Incorporated (VRTX) rose as much as 7% after hours on Monday after the company announced ...

An unprecedented effort to reverse the effects of a racially biased medical test that blocked or delayed Black people from ...

Patients with a particular histopathologic phenotype may respond less well to rituximab, but it is still unclear what factors ...

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age. Symptoms include absent menses, low estrogen levels, ...